STOCK TITAN

Cidara Therapeutics, Inc. - CDTX STOCK NEWS

Welcome to our dedicated page for Cidara Therapeutics news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics stock.

Cidara Therapeutics, Inc. (CDTX), headquartered in San Diego, California, is a pioneering biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. The company's mission is to address diseases inadequately treated by current standard of care therapies. Utilizing its proprietary Cloudbreak® platform, Cidara develops drug-Fc conjugates (DFCs) aimed at saving lives and improving patient outcomes for serious diseases such as cancer, viral infections, and autoimmune diseases.

The company's core portfolio includes:

  • Rezafungin (REZZAYO™): An FDA and EC-approved treatment for invasive candidiasis, licensed to multiple partners for commercialization in the U.S. and internationally.
  • CD101 IV: A potential once-weekly intravenous therapy for systemic fungal infections.
  • CD101 Topical: The first topical application of the echinocandin class of anti-fungals for vulvovaginal candidiasis (VVC).
  • CD388: A long-acting antiviral investigational drug for the prevention of all strains of influenza A and B, currently in Phase 2b development.

Recent achievements include significant data presentations at prestigious conferences and strategic realignments to focus on the most promising components of their pipeline. Cidara’s financial stability is reinforced by a $240 million private placement led by RA Capital Management, with participation from top-tier investors like Bain Capital Life Sciences and Biotech Value Fund (BVF).

Noteworthy partnerships include collaborations with Johnson & Johnson for CD388 and Mundipharma for the divestiture of rezafungin, which has led to substantial cost savings and allows Cidara to focus on its Cloudbreak platform. The company is also preparing for a Phase 2b clinical trial of CD388, aiming to deliver universal, season-long protection against influenza.
For more information, visit www.cidara.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.53%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
conferences covid-19

FAQ

What is Cidara Therapeutics' primary focus?

Cidara Therapeutics focuses on discovering, developing, and commercializing novel anti-infectives and immunotherapies for diseases inadequately treated by current therapies.

What is the Cloudbreak® platform?

The Cloudbreak® platform is Cidara's proprietary technology used to develop drug-Fc conjugates (DFCs) that target serious diseases by combining small molecules and peptides with human antibody fragments.

What are some of Cidara's key products?

Key products include REZZAYO™ (rezafungin) for invasive candidiasis, CD101 IV for systemic fungal infections, CD101 Topical for vulvovaginal candidiasis, and CD388 for the prevention of influenza A and B.

Has Cidara received any approvals for its products?

Yes, Cidara has received FDA and EC approval for REZZAYO™ (rezafungin) for the treatment of invasive candidiasis.

What recent strategic decisions has Cidara made?

Cidara recently divested rezafungin to Mundipharma, resulting in significant cost savings, and reacquired the global rights to CD388 from Johnson & Johnson to focus on their Cloudbreak platform.

How is Cidara funded?

Cidara is funded through investments, including a $240 million private placement led by RA Capital Management, and milestone payments from collaborations with partners like Mundipharma and Johnson & Johnson.

What upcoming clinical trials does Cidara have?

Cidara is planning to initiate a Phase 2b clinical trial to evaluate the efficacy and safety of CD388 as a universal preventative for influenza.

Where is Cidara Therapeutics headquartered?

Cidara Therapeutics is headquartered in San Diego, California.

Who are Cidara's major partners?

Major partners include Johnson & Johnson for CD388 and Mundipharma for rezafungin.

How can I get more information about Cidara?

For more information, you can visit Cidara's official website at www.cidara.com.

Cidara Therapeutics, Inc.

Nasdaq:CDTX

CDTX Rankings

CDTX Stock Data

59.35M
4.56M
7.34%
29.55%
2.49%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO